Delving into the Latest Updates on Immune Modulation, Inc. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

BACKGROUNDDeposition of α-synuclein and neuroinflammation are key pathological features of Parkinson's disease (PD). There is no cure for the disease; however, targeting the pathological features might be available to modulate the disease onset and progression. Hypoestoxide (HE) has been demonstrated as a NF-κB modulator, thereby acting as a potential anti-inflammatory and anti-cancer drug.METHODSIn order to assess the effect of HE in a mouse model of PD, mThy1-α-syn transgenic mice received intraperitoneal (IP) injections of either vehicle or HE (5 mg/kg) daily for 4 weeks.RESULTSTreatment of HE decreased microgliosis, astrogliosis, and pro-inflammatory cytokine gene expression in α-syn transgenic mice. HE administration also prevented the loss of dopaminergic neurons and ameliorated motor behavioral deficits in the α-syn transgenic mice, and α-synuclein pathology was significantly reduced by treatment of HE. In addition, increased levels of nuclear phosphorylated NF-κB in the frontal cortex of α-syn transgenic mice were significantly reduced by HE administration.CONCLUSIONSThese results support the therapeutic potential of HE for PD and other α-synuclein-related diseases.

Journal of Neurology & Neurophysiology

Short Review of Current Research on the Development of Hypoestoxide as a Therapeutic Agent for Parkinsons Disease

Author: Ojo-Amaize, Emmanuel A. ; Cottam, Howard B.

Parkinson's disease (PD) is a common neurodegenerative disorder belonging to a heterogeneous group of disorders with α-synuclein pathol. and PD dementia.Hypoestoxide is being developed to combat microgliosis, astrogliosis, loss of dopaminergic neurons, motor behavioral deficits and α-synuclein pathol. in PD.

100 Deals associated with Immune Modulation, Inc.

Login to view more data

100 Translational Medicine associated with Immune Modulation, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

2

Other

Login to view more data